BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Niu ZS, Wang WH. Circular RNAs in hepatocellular carcinoma: Recent advances. World J Gastrointest Oncol 2022; 14(6): 1067-1085 [DOI: 10.4251/wjgo.v14.i6.1067] [Reference Citation Analysis]
2 Qin S, Xu J, Yi Y, Jiang S, Jin P, Xia X, Ma F. Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma. Front Oncol 2021;11:691115. [PMID: 34307154 DOI: 10.3389/fonc.2021.691115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Wang RQ, He FZ, Meng Q, Lin WJ, Dong JM, Yang HK, Yang Y, Zhao M, Qiu WT, Xin YJ, Zhou ZL. Tribbles pseudokinase 3 (TRIB3) contributes to the progression of hepatocellular carcinoma by activating the mitogen-activated protein kinase pathway. Ann Transl Med 2021;9:1253. [PMID: 34532390 DOI: 10.21037/atm-21-2820] [Reference Citation Analysis]
4 Sun L, Cen W, Tang W, Deng L, Wang F, Ji X, Yang J, Zhang R, Zhang X, Du Z, Mei J. Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy. Disease Markers 2022;2022:1-9. [DOI: 10.1155/2022/7640560] [Reference Citation Analysis]
5 Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e27673. [PMID: 34713864 DOI: 10.1097/MD.0000000000027673] [Reference Citation Analysis]
6 Fang Y, Yan D, Wang L, Zhang J, He Q. Circulating microRNAs (miR-16, miR-22, miR-122) expression and early diagnosis of hepatocellular carcinoma. J Clin Lab Anal 2022;:e24541. [PMID: 35666610 DOI: 10.1002/jcla.24541] [Reference Citation Analysis]
7 Chang C, Wang MJ, Bi XF, Fan ZY, Feng D, Cai HQ, Zhang Y, Xu X, Cai Y, Qi J, Wei WQ, Hao JJ, Wang MR. Elevated serum eotaxin and IP-10 levels as potential biomarkers for the detection of esophageal squamous cell carcinoma. J Clin Lab Anal 2021;35:e23904. [PMID: 34288108 DOI: 10.1002/jcla.23904] [Reference Citation Analysis]
8 Du L, Wang M, Li H, Li N, Wang F, Mei J. Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-7. [DOI: 10.1155/2022/7758735] [Reference Citation Analysis]
9 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
10 Liao M, Wang C, Zhang B, Jiang Q, Liu J, Liao J. Distinguishing Hepatocellular Carcinoma From Hepatic Inflammatory Pseudotumor Using a Nomogram Based on Contrast-Enhanced Ultrasound. Front Oncol 2021;11:737099. [PMID: 34692513 DOI: 10.3389/fonc.2021.737099] [Reference Citation Analysis]